Home > News > Adjuvant Pertuzumab and Trastuzumab in EarlyHuman Epidermal Growth Factor Receptor 2-PositiveBreast Cancer in the APHINITY Trial: Third InterimOverall
Adjuvant Pertuzumab and Trastuzumab in EarlyHuman Epidermal Growth Factor Receptor 2-PositiveBreast Cancer in the APHINITY Trial: Third InterimOverall Survival Analysis With Efficacy Update